Get the Stockscreener App
10.60
2.84%
-0.31
After Hours:
10.60
Benitec Biopharma Inc stock is traded at $10.60, with a volume of 227.01K.
It is down -2.84% in the last 24 hours and down -9.01% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$10.91
Open:
$10.82
24h Volume:
227.01K
Relative Volume:
1.25
Market Cap:
$364.16M
Revenue:
$7,000
Net Income/Loss:
$-34.48M
P/E Ratio:
-10.54
EPS:
-1.0054
Net Cash Flow:
$-22.13M
1W Performance:
-5.27%
1M Performance:
-9.01%
6M Performance:
-23.80%
1Y Performance:
-13.11%
1-Day Range:
$10.25
$11.00
1-Week Range:
$10.25
$11.25
52-Week Range:
$9.85
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
10.60 | 374.81M | 7,000 | -34.48M | -22.13M | -1.0054 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
HC Wainwright Issues Optimistic Forecast for BNTC Earnings - MarketBeat
Research Analysts Offer Predictions for BNTC Q1 Earnings - Defense World
Analysts Issue Forecasts for BNTC Q1 Earnings - MarketBeat
(BNTC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Benitec Biopharma Inc. (BNTC) - DirectorsTalk Interviews
Benitec BioPharma stock rating maintained on gene therapy data - Investing.com Nigeria
Benitec BioPharma stock rating maintained on gene therapy data By Investing.com - Investing.com Australia
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan
Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (BNTC) Price Events - Stock Traders Daily
What insider trading reveals about Benitec Biopharma Inc. stockJuly 2025 Opening Moves & Verified Swing Trading Watchlists - mfd.ru
Growth Value: What insider trading reveals about Benitec Biopharma Inc. stockMarket Trend Summary & Smart Money Movement Alerts - mfd.ru
Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation - Yahoo Finance
Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st
Wall Street Zen Downgrades Benitec Biopharma (NASDAQ:BNTC) to Sell - MarketBeat
BNTC PE Ratio & Valuation, Is BNTC Overvalued - Intellectia AI
Benitec Biopharma (NASDAQ:BNTC) Announces Quarterly Earnings Results - MarketBeat
Benitec Biopharma Inc. (BNTC) Investor Outlook: Analyst Ratings Signal a Promising 104.58% Upside Potential - DirectorsTalk Interviews
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update - The Manila Times
Benitec Biopharma Q2 net loss widens - TradingView
BENITEC BIOPHARMA ($BNTC) Releases Q2 2026 Earnings - Quiver Quantitative
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
Is Benitec Biopharma Inc. exposed to political riskSwing Trade & Community Trade Idea Sharing Platform - mfd.ru
Guidance Update: Is Benitec Biopharma Inc forming a breakout patternTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Why (BNTC) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Benitec Biopharma (BNTC) Projected to Post Earnings on Friday - MarketBeat
Franklin Resources Inc. Expands Stake in Benitec Biopharma Inc. - GuruFocus
How liquid is Benitec Biopharma Inc stockWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Income Plays: Is Benitec Biopharma Inc stock a good dividend stock2025 Key Lessons & Expert-Curated Trade Recommendations - baoquankhu1.vn
Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade - Seeking Alpha
Meme Stocks: Is NATH stock a good pick for beginnersInflation Watch & Weekly High Return Forecasts - baoquankhu1.vn
BNTC Stockholders Sell Shares Without Benefit to Company - GuruFocus
Benitec Biopharma Inc. (BNTC) Investor Outlook: Analysts Predict Nearly 100% Upside Potential - DirectorsTalk Interviews
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Can Benitec Biopharma Inc. maintain its current growth rateJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - mfd.ru
Understanding Momentum Shifts in (BNTC) - Stock Traders Daily
Analyst Downgrade: Should I average down on GBTG stockJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Hedge Fund Bets: Is Benitec Biopharma Inc forming a double bottomJuly 2025 Catalysts & Short-Term High Return Ideas - baoquankhu1.vn
Benitec Biopharma Limited (NASDAQ:BNTC) Sees Large Increase in Short Interest - MarketBeat
Avoiding Lag: Real-Time Signals in (BNTC) Movement - Stock Traders Daily
Aug Setups: Will Benitec Biopharma Inc face regulatory challengesTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Aug Gainers: How supply chain issues affect Benitec Biopharma Inc stockEarnings Summary Report & Free High Accuracy Swing Entry Alerts - Bộ Nội Vụ
Citizens reiterates Market Outperform rating on Benitec BioPharma stock By Investing.com - Investing.com Canada
Market Wrap: What is the PEG ratio of Benitec Biopharma Inc2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Baird reiterates Outperform rating on Benitec BioPharma stock at $30 target - Investing.com Canada
Baird reiterates Outperform rating on Benitec BioPharma stock at $30 target By Investing.com - Investing.com South Africa
Benitec Biopharma (BNTC) Reports Promising Results from BB-301 S - GuruFocus
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '25 |
Buy |
12.85 |
50,000 |
642,500 |
9,620,075 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 26 '25 |
Buy |
13.10 |
16,836 |
220,552 |
9,634,395 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 22 '25 |
Buy |
12.08 |
19,542 |
236,067 |
9,577,475 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 19 '25 |
Buy |
11.48 |
16,384 |
188,088 |
9,560,825 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 18 '25 |
Buy |
11.24 |
10,215 |
114,817 |
9,546,875 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 07 '25 |
Buy |
13.50 |
1,481,481 |
19,999,994 |
9,538,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 31 '25 |
Buy |
12.83 |
16,497 |
211,736 |
8,807,805 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):